지연성 운동장애에 대한 Bromocriptine 의 치료 효과

Bromocriptine in the Treatment of Tardive Dyskinesia

In this dobule-blind clinical tria l of bromocrip-tine, the author tried to evaluate the efficacy of bromocriptine in the treatment of tardive dyskinesia and to prove the relevance of supersensitivity theory of brain dopaminergic system as a hypothesis of pathophysiology of tardive dyskinesia. Research subjects were selected from schizophrenic inpatients of National Seoul Mental Hospital by Schooler and Kane (1982)，s inclusion criteria. Twenty one chronic schizophrenic patients with tardive dyskinesia were fin ally selected as research samples. The A b no rm al Involuntary Movement Scale provided by N ational Institute of Mental Health in America was used for assessment of severity of dyskinesia and the Brief Psychiatric Ratin g Scale was used fo r evaluation of mental symptom change. The results were as follows； 1) There was no significant improvement of involuntary movements could statistically be proved in the bromocriptine-treated group. However, a slight improvement of involuntary movements could be noticed in 8 among 11 cases in bromocriptine group. Thus, possible action of bromcriptine as a partial dopamine agonist could not be excluded. 2) During the research period, m any drop-out cases were noticed in placebo group due to exacerbation of mental symptoms. Meanwhile, there were a few dropout in bromocriptine group. By this result, antipsychotic evidence of bromocriptine was vaguely suggested. At the present situation, however, theoretical implication of bromocriptine to antipsychotic effect is impossible to formulate. But, it is suggested th a t since the m ajority of persistent dyskinesia were the chronic schizophrenics, antidyskinesic agents should either have an tipsychotic property or well be tolerated w ith an tipsychotic agents for the successful management of tardive dyskinesia.